ArticleScientific reports2021
Metabolic engineering of probiotic Escherichia coli for cytolytic therapy of tumors.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 50 citations in OpenAlex.
- A bacteria-releasing mucoadhesive sheet for localized delivery and penetrative therapy of gastrointestinal cancer.Materials today. Bio · 2026Article
- Bioengineered systems to exploit tumor microenvironment metabolism.Trends in cancer · 2026Review
- Living Microbial Drugs.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Review
- Stage-Specific carcinogenic mechanisms and intervention strategies for pksArchives of microbiology · 2026Review
- Gut Microbiota and Extraintestinal Cancers: Mechanistic Insights and Microbiome-Targeted Interventions.JGH open : an open access journal of gastroenterology and hepatology · 2026Review
- Tigecycline suppresses colon cancer stem cells and impairs tumor engraftment by targeting SNAI1-regulated epithelial-mesenchymal transition.Acta pharmacologica Sinica · 2026Article
- Advances in the engineering of living probiotics for cancer immunotherapy.Theranostics · 2026Review
- Probiotic Bacteria as Therapeutics and Biohybrid Drug Carriers: Advances, Design Strategies, and Future Outlook.ACS applied bio materials · 2025Review
- Oncolytic bacteria: A revolutionary approach to cancer therapy.Open life sciences · 2025Review
- Effects of gut microbiota in breast cancer.Frontiers in oncology · 2025Review
- Metabolites in the Dance: Deciphering Gut-Microbiota-Mediated Metabolic Reprogramming of the Breast Tumor Microenvironment.Cancers · 2024Review
- Engineered Cancer Nanovaccines: A New Frontier in Cancer Therapy.Nano-micro letters · 2024Review
- Review
- Bacteria extracellular vesicle as nanopharmaceuticals for versatile biomedical potential.Nano convergence · 2024Review
- A Review of the Use of Native and Engineered Probiotics for Colorectal Cancer Therapy.International journal of molecular sciences · 2024Review
- Enhancing tumor-specific recognition of programmable synthetic bacterial consortium for precision therapy of colorectal cancer.NPJ biofilms and microbiomes · 2024Article
- Advances in anti-tumor based on various anaerobic bacteria and their derivatives as drug vehicles.Frontiers in bioengineering and biotechnology · 2023Review
- Fine-tuning Bacterial Cyclic di-AMP Production for Durable Antitumor Effects Through the Activation of the STING Pathway.Research (Washington, D.C.) · 2023Article
- Polymer Encapsulation of Bacterial Biosensors Enables Coculture with Mammalian Cells.ACS synthetic biology · 2022Article
- Native and Engineered Probiotics: Promising Agents against Related Systemic and Intestinal Diseases.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial cancer therapy was developed using probiotic Escherichia coli Nissle 1917 (EcN) for medical intervention of colorectal cancer. EcN was armed with HlyE, a small cytotoxic protein, under the control of the araBAD promoter (P
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.